China's National Medical Products Administration Center for Food and Drug Inspection (CFDI) published a notice on November 18, 2026 soliciting comments on the Medical Surgical Robot Inspection Points (Draft for Comments) (医用手术机器人检查要点(征求意见稿)). The notice states that CFDI drafted the points to standardise and guide on-site quality management system inspections of medical surgical robots, and that comments are due before December 10, 2026.

Chinese-registered manufacturers of medical surgical robots, importers and domestic responsible persons for foreign surgical robots placed on the Chinese market, and contract manufacturers and OEM suppliers who place surgical robots on that market and will face the CFDI on-site quality management system inspection must review the draft inspection points, submit feedback to CFDI by December 10, 2026, and then prepare their quality management system and technical documentation for those inspections, or their comments will not be on the CFDI record and the finalized points will still be the criteria CFDI uses in those inspections.

What does the draft inspection points cover?

The CFDI notice of November 18, 2026 says only that the center drafted the Medical Surgical Robot Inspection Points (Draft for Comments) to standardise and guide on-site quality management system inspections of medical surgical robots, and that it is now seeking public comments. It does not describe chapter contents, design controls, production controls, traceability or post-market duties. Comments go to [email protected] before December 10, 2026, using the feedback form. The notice attaches two files: the draft inspection points (医用手术机器人检查要点-征求意见稿.pdf) and the feedback form (意见反馈表.xlsx).

StepDate
CFDI publishes the notice and the draftNovember 18, 2026
Comments due at [email protected]December 10, 2026

Who is exposed to the CFDI inspection?

The exposed actors are the companies that place medical surgical robots on the Chinese market and will face the CFDI on-site quality management system inspection the draft is written to guide. Chinese-registered manufacturers of medical surgical robots are inspected on their own quality management system. Importers and domestic responsible persons for foreign surgical robots placed on the Chinese market must be ready for the same inspection of the product they place on that market. Contract manufacturers and OEM suppliers of surgical robot subsystems for the Chinese market are exposed where their production sits inside the quality system the registrant presents to CFDI.

The wider device regime those inspections sit under is State Council Order No. 739, the Regulations on the Supervision and Administration of Medical Devices. A Class III medical device, under China's three-class risk pathway in State Council Order 739, is a high-risk device whose registration and quality management system inspections are handled centrally by NMPA. The CFDI notice does not classify surgical robots under that pathway. Product Technical Requirements remain part of the Order 739 registration file the framework describes, and a Medical Device Registration Certificate under that order is valid for 5 years.

Obsidian tracks 3 regulatory texts (in force, amended or in preparation) under the CN Medical Device Regulation (Order 739) in China, as of November 2026.

What must manufacturers do before December 10, 2026?

December 10, 2026 is the date the notice sets for sending the feedback form to [email protected]. Manufacturers, importers, domestic responsible persons and their contract manufacturers use the period before that date to read the draft and put comments on the CFDI record, then prepare the quality management system and technical documentation the inspection will examine.

  • Download the draft inspection points and the feedback form from the CFDI notice and send them to regulatory affairs and quality leads.
  • Read each draft point against the current quality management system and the Product Technical Requirements and note gaps before the points are finalized.
  • Return the completed feedback form to [email protected] before December 10, 2026.
  • Prepare the quality management system and the technical documentation so they can be shown in a CFDI on-site quality management system inspection once the points are finalized.
  • Tell contract manufacturers and OEM suppliers which draft points touch the production they perform for the Chinese market.

What do the finalized points change for an inspection?

The finalized points are the criteria CFDI will use in on-site quality management system inspections of medical surgical robots. The notice does not state that a failed inspection blocks or delays registration or renewal, and it does not set a penalty for missing the comment window. A Medical Device Registration Certificate under State Council Order No. 739 is valid for 5 years. That validity period is a fact of the framework, not an effect the notice attaches to this draft. Continuous, per-jurisdiction monitoring of CFDI and NMPA consultations surfaces a draft like this the moment it publishes, so quality teams can file comments before the window closes.

Live
China NMPA medical devices: Order 739 implementation, registration and clinical evaluation rules
Monitor Chinese medical device regulation for the life sciences and medtech industry, for Swiss manufacturers registering devices in China.
Email 50+ news

Assign an owner for the feedback form, confirm that manufacturers, importers, domestic responsible persons and contract manufacturers who place surgical robots on the Chinese market have the draft, and send comments to [email protected] before December 10, 2026. Then prepare the quality management system and technical documentation against the criteria CFDI will apply in the on-site inspection.